Recursion — Portfolio Company | Sahin Boydas Angel Investments AI-powered drug discovery platform mapping biology at scale.
Written by Sahin Boydas — serial entrepreneur, 2x exited founder, and angel investor in 207+ startups including OpenAI, Anthropic, Scale AI, and Hugging Face.
About Recursion
AI-powered drug discovery platform mapping biology at scale. Recursion represents the kind of company I look for as an angel investor — strong technical founders building in a large market with clear differentiation.
Sector: Biotech
Why I Invested
Recursion caught my attention because of the team's deep domain expertise and their unique approach to solving a fundamental problem in biotech. The market opportunity is massive, and the team has the technical chops to capture it.
Investment Thesis
My investment in Recursion reflects my broader thesis on biotech:
- Large addressable market — The biotech market is growing rapidly with significant room for disruption
- Strong technical moat — The team has built proprietary technology that's difficult to replicate
- Proven execution — Early traction demonstrates product-market fit and team capability
- Network effects — The product gets better as more users adopt it
Related Investments
Other companies in my portfolio working in biotech and adjacent spaces:
Frequently Asked Questions
What does Recursion do?
AI-powered drug discovery platform mapping biology at scale.
Why did Sahin Boydas invest in Recursion?
Recursion represents a compelling opportunity in biotech with strong technical founders, a large market, and clear product-market fit. The investment aligns with my thesis on backing category-defining companies early.
What sector is Recursion in?
Recursion operates in the biotech sector, which is one of the fastest-growing areas of technology investment.
How does Recursion fit in Sahin's portfolio?
Recursion is one of 207+ angel investments in my portfolio, which spans AI, fintech, robotics, developer tools, healthcare, and more. I look for companies with strong technical moats and large addressable markets.